Biosynthetic Versus Synthetic Mesh in Oncologic Ventral Hernia Repair

Area of Science:

• Reconstructive Surgery
• Oncology
• Biomaterials

Background:

• Ventral hernia repair in cancer patients presents unique challenges due to compromised tissue quality and patient health.
• Limited comparative data exists for biosynthetic (Poly-4-hydroxybutyrate) versus synthetic mesh in oncologic ventral hernia repair.
• This study addresses the need for evidence comparing these mesh types in a high-risk patient cohort.

Purpose of the Study:

• To compare the outcomes of ventral hernia repair using biosynthetic versus synthetic mesh in oncologic patients.
• To assess complication rates and hernia recurrence between the two mesh types.
• To identify surgical factors influencing outcomes in this population.

Main Methods:

• Retrospective review of 207 oncologic patients undergoing ventral hernia repair between 2010 and 2023.
• Repairs utilized either biosynthetic or synthetic mesh in retrorectus, underlay, or onlay configurations.
• Primary endpoints included complication rates (hematoma, infection, dehiscence, abscess, seroma) and hernia recurrence.

Main Results:

• No significant differences in overall complication rates (biosynthetic 24% vs. synthetic 18%) or hernia recurrence (biosynthetic 8.8% vs. synthetic 6.7%) were observed.
• Subgroup analyses confirmed consistent findings across wound classes.
• Retromuscular mesh placement and bilateral external abdominal oblique release were associated with significantly lower recurrence risk.

Conclusions:

• Biosynthetic mesh demonstrates comparable safety and efficacy to synthetic mesh for ventral hernia repair in oncologic patients.
• Biosynthetic mesh represents a reasonable alternative for this challenging patient group.
• Specific surgical techniques are crucial for optimizing outcomes in oncologic ventral hernia repair.